Core Insights - The article discusses the rise of a family business empire valued at over 80 billion, founded by a couple who transitioned from academia to entrepreneurship, highlighting their journey and strategies in the collagen industry [1] Group 1: Company Background - Fan Daidi, born in 1966, became China's first female PhD in biochemical engineering and returned to Northwest University to lead research in human-derived collagen after visiting MIT in 2000 [2] - In 2000, her husband, Yan Jianya, left his stable job to start a business, establishing Xi'an Juzhi Biological Gene Technology Co., Ltd. in an 18-square-meter office, marking the beginning of their family business empire [2] Group 2: Business Development - The turning point for Juzhi Biological came in 2009 with the launch of their first commercial brand, Keli Jin, and the establishment of Xi'an Chuangke Village, which became a major distributor for the company [3] - The company adopted a tiered agency model, allowing individuals to become distributors for a fee, which significantly increased their customer base and sales [3] - From 2019 to 2021, Xi'an Chuangke Village contributed 52.2%, 49.3%, and 29.3% to Juzhi Biological's revenue, respectively, before the company shifted focus to online sales [3][4] Group 3: Revenue Growth and Market Position - By 2021, online direct sales accounted for 41.5% of total revenue, showcasing a significant shift in sales strategy [5] - On November 11, 2021, Juzhi Biological's brand Kefu Mei achieved over 100 million in sales within 13 minutes, marking a peak moment for the company [6] - The company's revenue grew from 957 million in 2019 to 5.538 billion in 2024, with a compound annual growth rate of 42% and a gross margin of 87.2% [6] Group 4: IPO and Leadership Transition - In 2022, the company went public in Hong Kong, becoming the first listed company in the collagen restructuring sector [7] - In 2023, Fan Daidi stepped down as executive director, passing the leadership to their daughter, Yan Yubo, raising questions about the next generation's ability to lead [8] Group 5: Challenges and Controversies - The company faces challenges such as high marketing costs, dependency on a single brand (Kefu Mei), and controversies regarding product integrity and compliance with industry standards [8] - From 2022 to 2024, Kefu Mei accounted for 68.2%, 79.1%, and 87.04% of total revenue, indicating a heavy reliance on this brand [8] - Reports of banned substances in Kefu Mei and allegations of product authenticity have emerged, highlighting the need for clearer industry standards [8][9]
缔造巨子生物“神话”，陕西首富发家史大揭秘